OSR Health, Inc.
OSRHNasdaq
$0.47
↓ -3.8%Jul 17 close · end-of-day
Price
1Y↓ -55.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$16.0M
Enterprise Value
$14.9M
P/E
2.9
P/S
6.1
P/B
0.1
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$2.6M
Net Income (TTM)
—
Free Cash Flow (TTM)
—
Gross Margin
22.2%
Operating Margin
-726.1%
Net Margin
—
ROE
—
ROIC
-11.9%
Debt / Equity
0.0
Net Cash
$1.1M
Return 1Y
-53.3%
Company profile
OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D "platform technologies" versus "assets only" companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea.
- CEO
- Harry Kim
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Headquarters
- Washington
- Website
- www.osr-holdings.com
Earnings
OSRH Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$484,057.41↓ -36.4%
Diluted EPS-$0.08↓ -92.3%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $3.5M | $2.9M |
| Gross profit | — | — | — | $811,236.00 | $592,905.00 |
| Operating income | -$3,308.00 | -$35,388.00 | -$1.8M | -$11.7M | -$18.3M |
| Net income | -$3,308.00 | -$35,388.00 | $403,780.00 | -$2.4M | — |
| Diluted EPS | — | -$0.01 | $0.05 | -$4.79 | -$0.80 |
| Operating cash flow | -$461.00 | -$4,235.00 | -$818,766.00 | -$1.8M | -$4.3M |
| Free cash flow | — | — | — | — | — |
| Gross margin | — | — | — | 23.0% | 20.4% |
| Operating margin | — | — | — | -331.2% | -631.0% |
| Net margin | — | — | — | -68.3% | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $881,829.00 | $822,996.00 | $915,253.00 | $761,271.53 | $1.1M | $627,747.00 | $381,269.47 | $484,057.41 |
| Gross profit | $232,321.00 | $179,093.00 | $160,020.00 | $168,685.60 | $32,782.00 | $261,734.00 | $129,703.40 | $160,281.03 |
| Operating income | -$3.2M | -$3.6M | -$1.6M | -$2.9M | -$5.2M | -$3.8M | -$6.4M | -$3.7M |
| Net income | -$97,295.00 | -$230,961.00 | -$2.0M | — | — | — | — | — |
| Diluted EPS | -$0.02 | -$0.06 | -$4.70 | -$1.04 | $0.35 | $0.12 | -$0.23 | -$0.08 |
| Operating cash flow | -$483,215.00 | -$686,453.00 | -$181,030.00 | -$64,069.29 | -$482,608.71 | -$2.7M | -$1.1M | -$1.0M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | 26.3% | 21.8% | 17.5% | 22.2% | 2.9% | 41.7% | 34.0% | 33.1% |
| Operating margin | -364.0% | -433.4% | -176.2% | -383.3% | -460.5% | -605.9% | -1674.8% | -757.6% |
| Net margin | -11.0% | -28.1% | -220.9% | — | — | — | — | — |
Company news
Jul 2, 2026
- 18d agoCORRECTION FROM SOURCE: Emerging Growth Research Issues Flash Report on OSR Health, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Targetfinance.yahoo.com
- 18d agoEmerging Growth Research Issues Flash Report on OSR Health, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Targetfinance.yahoo.com
Jun 22, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.